Alkermes (NASDAQ:ALKS) Releases FY 2026 Earnings Guidance

Alkermes (NASDAQ:ALKS) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of -0.521–0.405 for the period, compared to the consensus EPS estimate of -0.090. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion.

Alkermes Price Performance

Alkermes stock traded down $0.77 during midday trading on Wednesday, reaching $35.49. The company’s stock had a trading volume of 1,203,633 shares, compared to its average volume of 2,232,984. The stock’s 50-day simple moving average is $31.53 and its 200-day simple moving average is $30.98. Alkermes has a 52-week low of $25.17 and a 52-week high of $36.60. The stock has a market capitalization of $5.90 billion, a P/E ratio of 24.81 and a beta of 0.31.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million during the quarter. As a group, equities research analysts expect that Alkermes will post -0.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ALKS shares. Wolfe Research started coverage on Alkermes in a research note on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price objective for the company. UBS Group restated a “buy” rating on shares of Alkermes in a research note on Wednesday. Wells Fargo & Company raised their price objective on Alkermes from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial upgraded Alkermes to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $43.00 target price on shares of Alkermes in a report on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.79.

Insider Buying and Selling at Alkermes

In other Alkermes news, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.20, for a total value of $67,528.80. Following the sale, the executive vice president directly owned 231,558 shares of the company’s stock, valued at approximately $7,687,725.60. This trade represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $33.40, for a total value of $300,600.00. Following the completion of the sale, the executive vice president directly owned 81,389 shares in the company, valued at approximately $2,718,392.60. The trade was a 9.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 39,102 shares of company stock valued at $1,265,090. Company insiders own 4.59% of the company’s stock.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Needham raised its price target to $50 and reiterated a “buy” rating, signaling strong analyst conviction and a sizable upside thesis for ALKS. Needham raises PT to $50
• Positive Sentiment: Wells Fargo bumped its target to $44 with an “overweight” call, adding further analyst support that can buoy investor sentiment. Wells Fargo raises PT to $44
• Positive Sentiment: Q1 results showed revenue strength (roughly $393M, +28% y/y) and EPS beating the analyst consensus, which supports the commercial momentum story—especially around LUMRYZ. Q1 press release / slide deck
• Positive Sentiment: Management commentary on the earnings call highlighted LUMRYZ momentum as a growth driver, which investors may view as evidence of sustainable top?line expansion. Earnings call highlights (LUMRYZ)
• Neutral Sentiment: Analyst and research writeups (including a Seeking Alpha piece on Alkermes’ sleep?medicine platform) provide additional context for longer?term upside but are less likely to move price intraday. Seeking Alpha analysis
• Neutral Sentiment: Large institutions hold the bulk of shares and have been increasing positions over recent quarters; that supports stability but is a gradual influence rather than an immediate catalyst. MarketBeat institutional holdings
• Negative Sentiment: Management updated FY?2026 guidance to a negative EPS range materially below consensus and issued slightly cautious revenue guidance versus street expectations—this guidance reset is the primary near?term negative for the stock. Zacks: Q1 & guidance coverage
• Negative Sentiment: An EVP executed a Rule 10b5?1 sale of ~2,034 shares; the trade is disclosed and small relative to major insider holdings but is being noted by the market. SEC Form 4 (insider sale)

Institutional Trading of Alkermes

Institutional investors have recently made changes to their positions in the company. Inceptionr LLC acquired a new stake in shares of Alkermes in the fourth quarter worth approximately $529,000. CIBC Bancorp USA Inc. purchased a new stake in Alkermes in the third quarter valued at $519,000. Tower Research Capital LLC TRC raised its position in Alkermes by 88.5% in the second quarter. Tower Research Capital LLC TRC now owns 13,710 shares of the company’s stock valued at $392,000 after purchasing an additional 6,437 shares during the period. Magnetar Financial LLC purchased a new stake in Alkermes in the fourth quarter valued at $383,000. Finally, Cibc World Markets Corp purchased a new stake in shares of Alkermes in the 4th quarter valued at $300,000. 95.21% of the stock is owned by institutional investors and hedge funds.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.